Articles by Jill Wechsler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jill Wechsler

Health Reform to Transform Coverage, Costs

Manufacturers will pay new fees but anticipate expanded drug use and safeguards for innovation.
May 2, 2010

Manufacturers will pay new fees but anticipate expanded drug use and safeguards for innovation.

Risks and Realities of REMS

FDA lacks resources to manage expanding postmarketing responsibilities.
Apr 2, 2010

FDA lacks resources to manage expanding postmarketing responsibilities.

Pharma Cheers Health Reform Legislation

After months of increasingly rancorous debate, the House finally approved legislation on Mar. 21, 2010, that makes significant changes in the nation's healthcare system.
Mar 22, 2010

After months of increasingly rancorous debate, the House finally approved legislation on Mar. 21, 2010, that makes significant changes in the nation's healthcare system.

Health IT Promises More Timely Drug Information

FDA modernizes information systems, expands access to drug safety and use information.
Mar 2, 2010

FDA modernizes information systems, expands access to drug safety and use information.

Manufacturers Look to Vaccines for Growth and Innovation

Vaccine R&D is surging, but continues to raise manufacturing and regulatory challenges.
Feb 2, 2010

Vaccine R&D is surging, but continues to raise manufacturing and regulatory challenges.

Pharma Faces Multiple Challenges in the Year Ahead

Globalization and reform initiatves will shape pharma production, pricing, and pipelines in 2010.
Jan 2, 2010

Globalization and reform initiatves will shape pharma production, pricing, and pipelines in 2010.

Generic Drugs Come of Age

Generic-drug manufacturers look to expand into biologics and complex dosage forms. This article contains bonus online-exclusive material.
Dec 2, 2009

Generic-drug manufacturers look to expand into biologics and complex dosage forms. This article contains bonus online-exclusive material.

Safety versus Speed in Drug Development

The heightened focus on risk raises concerns about delays in approving new drugs.
Nov 2, 2009

The heightened focus on risk raises concerns about delays in approving new drugs.

New Leadership Seeks to Transform FDA

Strict enforcement, new rules, and organizational changes signal an activist tone.
Oct 2, 2009

Strict enforcement, new rules, and organizational changes signal an activist tone.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here